摘要
目的评价重组人粒细胞集落刺激因子(rhG-CSF,造血生长因子)对小细胞肺癌化疗所致骨髓抑制的疗效。方法对解放军总医院2002年至2006年来222例小细胞肺癌患者病例进行回顾性调查,采集其中62例化疗后使用重组人粒细胞集落刺激因子进行治疗的病例,并对信息进行统计学分析。结果重组人粒细胞集落刺激因子可以有效缓解小细胞肺癌患者化疗后的骨髓抑制反应,使白细胞和中性粒细胞数目明显升高,平均恢复时间3天,有效率为95.2%。结论rhG-CSF对治疗小细胞肺癌化疗所致的骨髓抑制作用好,不良反应少;但对不同患者的不同情况,应调整剂量和用法。
Objective To evaluate the efficacy and safety of recombinant human granulocyte colony-stimulating factor （rhG-CSF） used for chemotherapy-induced myelosuppression in small cell lung cancer （SCLC） patients. Methods Two hyndreds twenty-two cases suffering from small cell lung cancer of PLA General Hospital from 2002 to 2006 were chosen in our retrospective study, and 62 of these cases, used rhG- CSF after chemotherapy,were included in a statistics analysis. Results rhG-CSF was effective for chemotherapy-induced myelosuppression reactions and increasing significantly the number of neutropenia leukocyte and WBC （white blood cell）. Average duration of recovery was 3 days and the effective rate was 95.2%. Conclusion rhG-CSF showed high overall response rate of chemotherapy-induced myelosuppression reaction with only a few adverse reactions. But dosage and administration should be adjusted to different patients in different situations.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2009年第6期501-504,共4页
The Chinese Journal of Clinical Pharmacology
关键词
重组人粒细胞集落刺激因子
小细胞肺癌
化疗
骨髓抑制
recombinant human granulocyte colony-stimulating factor
small cell lung cancer
chemotherapy
myelosuppression
